Association of Neoadjuvant Immunotherapy with Postoperative Major Morbidity After Oncologic Surgery

Daniel R. S. Habib BA¹, Matthew Shou BA¹, Kamran Idrees MD², Aimal Khan MD²

¹ Vanderbilt University School of Medicine, ² Vanderbilt University Medical Center Department of Surgery

Background


- Neoadjuvant immunotherapy (NI) has revolutionized cancer treatment.¹
- Extensive research on the impact of neoadjuvant chemotherapy² but not NI on surgical outcomes across cancer types
- Understanding the effect of NI on surgical complication risk informs patient education and selection for oncologic surgery.


Methods

- Primary outcome: Major morbidity³ = hospital length of stay within top decile of each surgery subtype, unplanned 30-day readmission, or 30day mortality
- Multivariable logistic regressions: Odds ratios of major morbidity from NI by cancer type
- Covariates: Demographics, Charlson-Deyo comorbidity index, clinical cancer staging, procedure type, surgical approach, and neoadjuvant chemotherapy and radiation

Daniel.r.habib@vanderbilt.edu







No association between NI and increased surgical complication risk for rectal, colon, anal, esophageal, non-small cell lung, and oral cavity

Discussion / Conclusions

- Limitations: Lack of detailed surgical complication data for each cancer type, small anal cancer sample size, and use of NCDB to study surgical outcomes
 - NCDB major morbidity as a composite surgical complication proxy has been validated. 3

References

- Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. *Cell Mol Immunol*. 2020;17(8):807-821. doi:10.1038/s41423-020-0488-6
- 2. Kraut J, Gippetti J, Peterson D, et al. Chemotherapy use near end of life (EOL): Measuring real world benchmarks. *J Clin Oncol*. 2017;35(8_suppl):228-228. doi:10.1200/JCO.2017.35.8_suppl.228
- 3. Wong L-Y, Liou DZ, Backhus LM, Lui NS, Shrager JB, Berry MF. The impact of neoadjuvant immunotherapy on perioperative outcomes and survival after esophagectomy for esophageal cancer. *JTCVS Open*. 2023;14:547-560. doi:10.1016/j.xjon.2023.03.015



cancers



20th Annual Scientific Session

